Advertisement Pharmaceutical Business review - Page 619 of 5279 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
July 1, 2026

Eli Lilly and Innovent agree Verzenios commercialisation deal in China

Eli Lilly and Company has entered into an agreement with Innovent Biologics for the commercialisation of Verzenios (abemaciclib) in mainland China.

Verzenios indicated for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer. Credit: Peakstock/Shutterstock.com.